Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Feb;8(1):91-98.
doi: 10.1177/2050640619895361. Epub 2019 Dec 12.

Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis

Affiliations
Observational Study

Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis

Thomas Ochsenkühn et al. United European Gastroenterol J. 2020 Feb.

Abstract

Background: Recently, ustekinumab a monoclonal antibody targeting interleukin-12 and -23 and successfully used in Crohn's disease also has been shown to be effective in induction and maintaining remission in patients with moderate to severe ulcerative colitis in a large phase 3 trial. However, no observational data on the use of ustekinumab in ulcerative colitis in daily clinical practice is available.

Aim: The purpose of this study was to assess the clinical outcomes achieved with ustekinumab as rescue treatment in therapy-refractory or -intolerant ulcerative colitis in a real-life setting.

Methods: A retrospective data analysis was performed in 19 ulcerative colitis patients who were intolerant or refractory to all of the following drugs: steroids, purine-analogues, tumour necrosis factor antibodies and vedolizumab. To all patients ustekinumab was provided as a rescue treatment (intravenous induction with 6 mg/kg, followed by week subcutaneous injection once every eight weeks of 90 mg). The primary outcome was achievement of clinical remission at one year, defined as score of ≤ 3 points in the Lichtiger score (colitis activity index). Patients were evaluated regularly and a colonoscopy was performed before the start and at the end of the observation. Ethical approval was provided by Ethikkommission Ärztekammer Hamburg (PV 5539).

Results: In five patients, therapy was stopped due to refractory disease or side effects. In all remaining 14 patients the median colitis activity index dropped from 8.5 points (range 1-12) at start to 2.0 points at one year (range 0-5.5) and Mayo endoscopy scores fell from a median of two points (range 1-3, mean of 2.3) at start to a median of one point (range 1-3, mean of 1.4) at one year. Including the five drop-outs, clinical remission was achieved in 53% of the 19 patients at one year.

Conclusions: In accordance with the UNIFI (A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis) trial our real-life data support ustekinumab as an effective and safe treatment option in therapy refractory moderate to severe ulcerative colitis with a history of biological therapies.

Keywords: Colonoscopy; colon; gastroenterology; inflammatory bowel disease; surgery; ulcerative colitis; ustekinumab.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow chart of 19 ulcerative colitis (UC) patients included in the observational trial. i.v.: intravenous; q8weekly: once every 8 weeks; s.c.: subcutaneous; UST: ustekinumab.
Figure 2.
Figure 2.
Endoscopic results in all 14 patients who continued ustekinumab up to at least one year.
Figure 3.
Figure 3.
Clinical outcome as measured by Lichtiger score (colitis activity index (CAI)), in all 19 patients throughout one year.
Figure 4.
Figure 4.
Calprotectin in all 10 patients who were in remission at one year, measured at the start and at one year.

Comment in

References

    1. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet 2017; 389: 1756–1770. - PMC - PubMed
    1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011; 365: 1713e25–1713e25. - PubMed
    1. Viscido A, Papi C, Latella G, et al. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics 2019; 13: 23–31. - PMC - PubMed
    1. Parragi L, Fournier N, Zeitz J, et al. Colectomy rates in ulcerative colitis are low and decreasing: 10-Year follow-up data from the Swiss IBD cohort study. J Crohns Colitis 2018; 12: 811–818. - PubMed
    1. Murthy SK, Begum J, Benchimol EI, et al. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: A population-based interrupted time series study. Gut. Epub ahead of print 12 June 2019. DOI: 10.1136/gutjnl-2019-318440. - PMC - PubMed

Publication types

MeSH terms